{"id":"rbp-6000","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hyperhidrosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"RBP-6000 is a long-acting subcutaneous injection containing buprenorphine, a partial agonist at the mu-opioid receptor. The depot formulation releases buprenorphine gradually over several weeks, maintaining therapeutic levels and reducing withdrawal symptoms and cravings in opioid use disorder. This extended-release approach improves medication adherence compared to daily oral formulations.","oneSentence":"RBP-6000 is a subcutaneous depot formulation of buprenorphine that provides sustained opioid receptor partial agonism for extended periods.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:21.236Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder (maintenance treatment)"}]},"trialDetails":[{"nctId":"NCT04995029","phase":"PHASE4","title":"Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2021-10-26","conditions":"Moderate to Severe Opioid-use Disorder","enrollment":785},{"nctId":"NCT03809143","phase":"PHASE3","title":"Community Studies of Long Acting Buprenorphine (CoLAB)","status":"UNKNOWN","sponsor":"The University of New South Wales","startDate":"2019-05-22","conditions":"Opioid Dependence","enrollment":100},{"nctId":"NCT03604861","phase":"","title":"An Observational Study of Environmental and SocioEconomic Factors in Opioid Recovery","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2015-08","conditions":"Opioid-use Disorder, Opioid-related Disorders","enrollment":534},{"nctId":"NCT02896296","phase":"PHASE3","title":"Open-Label Treatment Extension Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2016-08-17","conditions":"Opioid Use Disorder, Opioid-related Disorders","enrollment":208},{"nctId":"NCT02044094","phase":"PHASE2","title":"Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2013-11","conditions":"Opioid Use Disorder","enrollment":39},{"nctId":"NCT02510014","phase":"PHASE3","title":"Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2015-07-27","conditions":"Opioid Use Disorder, Opioid-related Disorders","enrollment":775},{"nctId":"NCT01738503","phase":"PHASE2","title":"Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2012-10","conditions":"Opioid Related Disorder","enrollment":124},{"nctId":"NCT02357901","phase":"PHASE3","title":"Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2015-01-28","conditions":"Opioid Dependence, Opioid Related Disorders","enrollment":665},{"nctId":"NCT02559973","phase":"PHASE1","title":"Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2015-09","conditions":"Opioid Use Disorder","enrollment":47},{"nctId":"NCT01582347","phase":"PHASE2","title":"Transfer of Subjects From Subutex/Suboxone to RBP-6300","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2012-03","conditions":"Opioid Related Disorder","enrollment":143},{"nctId":"NCT03002961","phase":"PHASE1","title":"Single Ascending Dose Study of RBP-6000","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2012-07","conditions":"Opioid Use Disorder","enrollment":48},{"nctId":"NCT02765867","phase":"PHASE1","title":"Single-dose, Study of RBP-6000 in Opioid Dependent Individuals","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2010-11","conditions":"Opioid Use Disorder","enrollment":18}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"OVERDOSE"},{"count":2,"reaction":"TOXICITY TO VARIOUS AGENTS"},{"count":1,"reaction":"ANXIETY"},{"count":1,"reaction":"DRUG ABUSE"},{"count":1,"reaction":"DRUG DIVERSION"},{"count":1,"reaction":"DRUG SCREEN POSITIVE"},{"count":1,"reaction":"DRUG WITHDRAWAL SYNDROME"},{"count":1,"reaction":"FEELING ABNORMAL"},{"count":1,"reaction":"HYPERHIDROSIS"},{"count":1,"reaction":"INJECTION SITE NODULE"}],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["atrigel buprenorphine","extended-release buprenorphine","Sublocade","Atrigel buprenorphine","buprenorphine"],"phase":"phase_3","status":"active","brandName":"RBP-6000","genericName":"RBP-6000","companyName":"Indivior Inc.","companyId":"indivior-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RBP-6000 is a subcutaneous depot formulation of buprenorphine that provides sustained opioid receptor partial agonism for extended periods. Used for Opioid use disorder (maintenance treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}